Bioengineering cobalt chromium cardiovascular stent biomaterial for surface enhancement and characterization

Jeewandara, Thamarasee

doi:10.15200/winn.145619.92147

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Samples of alloy L605 (10 cm x 8 cm x 0.025 cm) were prepared as before (Jeewandara 2016). All experiments were carried out with freshly made PAC, used within 2 weeks, unless stated otherwise.…”

Section: Preparation Of Cobalt Chromium Alloy L605 For Surface Modifimentioning

confidence: 99%

“…The present study utilized a proprietary applied plasma physics technique to modify the surface of cardiovascular stent material alloy L605. The plasmaactivated coating (PAC) constructs a buffer layer at the interface of organic and inorganic materials forming a robust surface; characterized previously on PAC-L605 (Jeewandara 2016). The surface modification is unique, non-delaminating and able to covalently bind tropoelastin (TE), a bioactive protein candidate of interest ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioengineering cobalt chromium cardiovascular stent biomaterial for biofunctionalization

Jeewandara

2016

Preprint

View full text Add to dashboard Cite

Suboptimal biocompatibility of cardiovascular stents manifest as non-compliance at stent-artery interface in vivo. We optimized a plasma-activated coating (PAC) technology to modify cobalt chromium alloy L605 (PAC-L605) surface of an implantable coronary stent material, for improved biofunctionalization. The PAC-L605 surfaces displayed covalent binding capacity of a protein candidate tropoelastin (TE) by retaining 70.3% of TE after SDS detergent washing. Human coronary artery endothelial cell (HCAEC) proliferation visualized with crystal violet staining, did not vary significantly among the biomaterials at 3 or 5 days. Anchorage of cell cytoskeleton visualized with immunofluorescence and scanning electron microscopy (SEM), showed homogenous cell morphology on PAC/TE (with TE) surfaces. Surface hemocompatibility was assessed with static and flow blood assays, the hydrophilic PAC-L605 displayed lower clot formation compared to L605. Area of surface fibrinogen deposited was significantly lower on PAC-L605 vs. L605. Selected ISO 10993-4 tests for biological evaluation of medical devices in contact with blood indicated significantly lowered plasma markers of thrombin-antithrombin complex (TAT), beta-thromboglobulin (β-TG), soluble P-selectin and soluble terminal complement complex (SC5b-9) on PAC-L605 vs. L605. There was no significant difference for plasma biomarkers of polymorphonuclear elastase (PMN elastase) on PAC-L605 vs. L605. Improved surface biofunctionalization of implantable cardiovascular materials could be achieved by plasma-activated coating (PAC).

show abstract

Section: Preparation Of Cobalt Chromium Alloy L605 For Surface Modifimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bioengineering cobalt chromium cardiovascular stent biomaterial for biofunctionalization

Jeewandara

2016

Preprint

View full text Add to dashboard Cite

show abstract

Bioengineering cobalt chromium cardiovascular stent biomaterial for surface enhancement and characterization

Cited by 1 publication

References 23 publications

Bioengineering cobalt chromium cardiovascular stent biomaterial for biofunctionalization

Bioengineering cobalt chromium cardiovascular stent biomaterial for biofunctionalization

Contact Info

Product

Resources

About